On 21 October 2026, Nucelion Therapeutics, a wholly owned subsidiary of Bharat Biotech, partnered with Hyderabad-based VeGen Bio to manufacture VL-2511, a dual-target CAR-T therapy, in India.
VL-2511 is a Phase II clinical-stage, first-in-class autologous CAR-T therapy that targets two antigens, BCMA and CD19, for multiple myeloma (a cancer of plasma cells).
Nucelion will be the technology-transfer and clinical- and commercial-stage manufacturing partner, at its GMP facility in Genome Valley, Hyderabad.
The aim is higher manufacturing yields and lower production costs, to widen access to CAR-T therapy in India.
A patient's own T cells are collected, engineered to carry a Chimeric Antigen Receptor that recognises a marker on cancer cells, multiplied outside the body and infused back. BCMA marks plasma cells; CD19 marks B-lineage cells.
Simple Analogy: Training the body's own guards to spot two badges instead of one.
Vaccine maker (Covaxin); parent company of Nucelion Therapeutics
National regulator for drugs and clinical trials, under the Ministry of Health and Family Welfare; headed by the Drugs Controller General of India
Regulates medicines and biological products in the United States
Evaluates medicines for the European Union
GS Paper III > Science and Technology > Biotechnology; GS Paper II > Health
General Science > Biology > Immunity and diseases
Treatment using cells taken from the same patient who receives them
Cancer cells losing or downregulating the antigen a therapy targets, letting them evade it
Contract research, development and manufacturing organisation